您所在的位置：急性白血病 >> 临床体现>>
>> 最新全球急性髓性白血病AML
最新全球急性髓性白血病AML
文章来源：急性白血病 发布时间:2021-3-5 8:27:49 点击数： 次
第二届药融圈CBV（CEO+BD+VC）高峰论坛，最终嘉宾日程曝光！高质量，免费学习交流机会。
正文：
最新：全球急性髓性白血病(AML)在研药物一览，本文来自于最近NRDD论文Theacutemyeloidleukaemiamarket。仅供参考。
详见：doi:10./d---4；NatureReviewsDrugDiscovery。
药物名称
公司
靶点机制
临床进展
Crenolanib
AROGPharmaceuticals
FLT3andPDGFR
PhaseIII
Guadecitabine
AstexPharmaceuticals/OtsukaPharmaceutical
DNAmethyltransferase
PhaseIII
Iomab-B
ActiniumPharmaceuticals
CD45
PhaseIII
CC-
Celgene
DNAmethyltransferase
PhaseIII
Uproleselan
GlycoMimetics
E-selectin
PhaseIII
Devimistat
RafaelPharmaceuticals/OnoPharmaceutical
Lipoateanalogue
PhaseIII
Idasanutlin
Roche
MDM2
PhaseIII
Pevonedistat
TakedaOncology
NAE
PhaseIII
Pracinostat
HelsinnHealthcare/MEIPharma
HDAC
PhaseIII
Alvocidib
ToleroPharmaceuticals/SumitomoDainippon
CDK9
PhaseII
Tamibarotene
SyrosPharmaceuticals
RARα
PhaseII
Onvansertib
Trovagene
PLK1
PhaseIb/II
Annamycin
MoleculinBiotech
Liposomalanthracycline
PhaseI/II
Flotetuzumab
MacroGenics/Servier
CD–CD3bispecificantibody
PhaseI/II
MB-
MustangBio
CDCARTcell
PhaseI
疾病市场预测：Major-marketsalesofkeytherapiesforacutemyeloidleukaemia,bydrugclass(estimated).Thefigureshowsthe–forecastforthesevenmajormarkets:theUnitedStates,France,Germany,Italy,Spain,UnitedKingdomandJapan.Bcelllymphoma2(BCL2)inhibitors:Venclexta/Venclyxto.FMS-liketyrosinekinase3(FLT3)inhibitors:Rydapt,Xospata,Vanflytaandcrenolanib.Hypomethylatingagents:azacitidineanddecitabine.Isocitratedehydrogenase1(IDH1)/IDH2inhibitors:IdhifaandTibsovo.Hedgehogpathwayinhibitors:Daurismo.Drugclasseswithexpectedsalesof$millioninnotshown.
更多前沿医药产业数据，扫码
